Free Trial

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 655.34 +7.34 (+1.13%)
As of 06:17 AM Eastern

IBT vs. RICA, SAIN, CGT, MUT, JEO, APEO, SLPE, ESCT, BLU, and SDP

Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include Ruffer Investment (RICA), Scottish American Investment (SAIN), Capital Gearing (CGT), Murray Income Trust (MUT), European Opportunities Trust (JEO), abrdn Private Equity Opportunities (APEO), Standard Life Private Equity Trust (SLPE), The European Smaller Companies Trust (ESCT), Blue Star Capital (BLU), and Schroder Investment Trust - Schroder AsiaPacific Fund (SDP). These companies are all part of the "asset management" industry.

International Biotechnology vs. Its Competitors

Ruffer Investment (LON:RICA) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

In the previous week, International Biotechnology had 1 more articles in the media than Ruffer Investment. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Ruffer Investment. Ruffer Investment's average media sentiment score of 0.00 equaled International Biotechnology'saverage media sentiment score.

Company Overall Sentiment
Ruffer Investment Neutral
International Biotechnology Neutral

International Biotechnology has higher revenue and earnings than Ruffer Investment. International Biotechnology is trading at a lower price-to-earnings ratio than Ruffer Investment, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ruffer Investment£16.91M54.03£8.78M£2.75103.27
International Biotechnology£41.82M5.63£37.91M£104.806.25

Ruffer Investment pays an annual dividend of GBX 5 per share and has a dividend yield of 1.8%. International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.4%. Ruffer Investment pays out 181.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology pays out 27.7% of its earnings in the form of a dividend. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

43.3% of Ruffer Investment shares are owned by institutional investors. Comparatively, 45.2% of International Biotechnology shares are owned by institutional investors. 0.2% of Ruffer Investment shares are owned by insiders. Comparatively, 4.2% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ruffer Investment has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

International Biotechnology has a net margin of 90.66% compared to Ruffer Investment's net margin of 51.94%. International Biotechnology's return on equity of 13.67% beat Ruffer Investment's return on equity.

Company Net Margins Return on Equity Return on Assets
Ruffer Investment51.94% 0.96% 0.45%
International Biotechnology 90.66%13.67%3.57%

Summary

International Biotechnology beats Ruffer Investment on 11 of the 14 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

MetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON Exchange
Market Cap£235.41M£1.29B£6.36B£3.07B
Dividend Yield4.20%4.41%4.19%5.02%
P/E Ratio6.2522.4214.14166.23
Price / Sales5.632,550.871,843.89308,656.68
Price / Cash155.7460.70127.2427.97
Price / Book0.861.452.264.53
Net Income£37.91M£265.04M£1.23B£5.90B
7 Day Performance3.04%0.59%0.98%1.25%
1 Month Performance9.59%0.77%2.25%3.70%
1 Year Performance-1.60%8.09%26.75%57.75%

International Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 655.34
+1.1%
N/A-2.7%£235.41M£41.82M6.25N/ANews Coverage
RICA
Ruffer Investment
N/AGBX 285
+0.2%
N/A-0.9%£917.06M£16.91M103.67N/A
SAIN
Scottish American Investment
N/AGBX 516.14
+0.2%
N/A+0.7%£902.51M£75.38M10.35N/AEarnings Report
CGT
Capital Gearing
N/AGBX 4,830
-0.2%
N/A+2.7%£898.26M£17.92M19.64N/ANews Coverage
MUT
Murray Income Trust
N/AGBX 894.46
-0.6%
N/A+2.9%£893.64M£97.96M9.86147,000Dividend Cut
JEO
European Opportunities Trust
N/AN/AN/AN/A£886.70M-£62.33M-12.93N/A
APEO
abrdn Private Equity Opportunities
N/AN/AN/AN/A£880.29M£80.21M1,435.00N/A
SLPE
Standard Life Private Equity Trust
N/AGBX 558
+1.5%
N/A+2.3%£857.90M£251.60M3.60N/A
ESCT
The European Smaller Companies Trust
N/AGBX 215.50
-0.2%
N/A+22.1%£850.01M£96.24M10.16305Positive News
BLU
Blue Star Capital
N/AGBX 16.53
-2.8%
N/A+99,275.0%£841.38M-£5.16M1.903
SDP
Schroder Investment Trust - Schroder AsiaPacific Fund
N/AGBX 593
-0.2%
N/A+15.5%£837.71M£134.70M6.92N/APositive News

Related Companies and Tools


This page (LON:IBT) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners